Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania. Show more

Four Tower Bridge, West Conshohocken, PA, 19428, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

9.943B

52 Wk Range

$265.00 - $615.00

Previous Close

$437.79

Open

$437.92

Volume

272,695

Day Range

$431.14 - $452.30

Enterprise Value

9.349B

Cash

1.11B

Avg Qtr Burn

N/A

Insider Ownership

7.86%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Rezdiffra (Resmetirom) (MGL-3196) Details Non-alcoholic steatohepatitis, Liver disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rezdiffra (Resmetirom) (MGL-3196) Details Liver disease, Cirrhosis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Resmetirom (MGL-3196) Details Fatty liver disease, Liver disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.